Send a Tweet
Most Popular Choices
Share on Facebook 6 Share on Twitter 1 Printer Friendly Page More Sharing
General News    H4'ed 4/9/20

Anti-Parasitic Drug Halts Coronavirus Replication in Lab-Grown Cells within 48 Hours

Author 2756
Follow Me on Twitter     Message Josh Mitteldorf
Become a Fan
  (53 fans)

An anti-parasitic drug available around the world stops SARS-CoV-2 coronavirus from replicating within a couple of days, according to findings from in vitro studies by Monash University, working with the Peter Doherty Institute of Infection and Immunity.

Kylie Wagstaff, PhD, said the studies showed that ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Wagstaff commented. The researchers’ report is available as a pre-proof paper in Antiviral Research, titled, “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.”

Ivermectin is approved by the FDA for treating a number of parasitic infections, and the drug has an established safety profile,

Read the rest of the story HERE:

At www.genengnews.com

 

Must Read 1   News 1   Valuable 1  
Rate It | View Ratings

Josh Mitteldorf Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in


Josh Mitteldorf, a senior editor at OpEdNews, blogs on aging at http://JoshMitteldorf.ScienceBlog.com. Read how to stay young at http://AgingAdvice.org.
Educated to be an astrophysicist, he has branched out from there to mathematical (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation: